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THE persistence of donor leukocvtes in recipients after 
transplantation (chimerism) has been postulated as 
the basis for graft acceptance. I.: There have been direct 
efforts to augment chimerism in order to increase the 
chance of graft acceptance. even though the mechanism of 
the bidirectional modulation between host and chimeric 
cells to achieve donor-specific hyporeactivity is not clear. In 
this study we examined the influence of donor bone marrow 
infusion at the time of solid organ transplantation on the 
levels of chimerism and the outcome of transplants. 
MATERIALS AND METHODS 
ACI (RTI") and Lewis (LEW. RTII) rats (Harlan Spragut:·Daw!ev. 
Indianapolis. Ind.) were used as donors and recipients. rcspec-
lIvclv. Orthotopic small bowel. livcr. and heterotopIc abdominal 
heart transplants were performed using the methods previously 
dcscnbed J ·4 Intramuscular FK 500 (Fujisawa Pharmaceutical Co. 
Ltd .. Osaka. Japan) was used at a daily dose of 1 mg/kg on days O. 
J. and 2. Bonc marrow cells werc obtained from tibias and femurs 
of naive ACI rats and 250 x 10" cells were infused to each recipient 
on the day of solid organ grafting. Whole organ graft survival and 
the incidence of graft·versus-host disease (GYHD) were examined 
With or without simultaneous bone marrow infusion. The percent-
ages of donor phenotvpe lymphocytcs In the recipient blood were 
analyzed by 110w cytometry uSing MAb specific for donor (ACI) 
major histocompatibility complex (MHC) class I (MN4-<J I-n. Sero-
ICC. UK). 
RESULTS 
:Y1edian heart graft survival of animals treated with a J-day 
course of FK 5(1) alone was 4~ days (n = h). The addition 
or donor bone marrow infusion on the day of heart grafting 
significantly (P < .(1) improved graft survival. and all 
~mimals survived more than 100 days (n = h). FK 506 
treatment alone prolonged small bowel graft survival to a 
median of 57.5 days (n = 6). These animals died exclusively 
of rejection without signs of GVHD. Interestingly. 5 of H 
animals developed GVHD (skin rash) between 20 and 35 
days after the simultaneous small bowel and bone marrow 
transplantation. GVHD was fatal in 4 of 5 :mimals and 
death occurred between 25 and 43 davs. One animal 
recovered from GVHD and survived for 200 days. at which 
time histopathological evidence of chronic rejection was 
noticed. The remaining 3 animals in this group were free 
trom GVHD: however. rejection was the primary cause 01 
animal death between 41 and 51 days after grafting. Finally. 
a median small bowel graft survival of 42 days with bone 
marrow infusion was slightlY shorter than that without bone 
marrow infusion. All FK 506 treated recipients of liver 
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grafts lived more than 100 days regardless of bone marrO\\ 
infusion. When the liver and bone marrow were trans-
planted together. 2 of 5 recipients showed temporary 
GVHD. which spontaneously resolved. 
Flow cytometric analysis revealed that bone marrow 
infusion increased the numbers of donor cells in the recip-
ient circulation. when compared with those after solid 
organ transplantation alone. Detection of donor cells by 
flow cytometry was difficult in recipients of heart grafts but 
relatively easy after liver transplantation. After small bowel 
grafting, especially with bone marrow infusion. donor cells 
remained in the recipients for a long time. They rapidly 
increased to 20S"r to hO'!/: in GYHD animals. but were not 
detected after recoverv from GVHD. 
DISCUSSION 
The engraftment of allogeneic cells with a state of donor-
specific tolerance has been achieved in cytoablated recipi-
ents of bone marrow transplantation.5 Consequently. the 
strategic use of donor bone marrow to establish acquired 
transplantation tolerance was commonly applied in combi-
nation with ALG. h As seen in this studv and in the results of 
a clinical trial. 7 bone marrow cell inf~sion along with solid 
organ transplantation affected the graft outcome through 
the engraftment of bone marrow cells under conyentional 
immunosuppression. The graft that profits most from this 
procedure may be the organ. which has relatively poorly 
distributed passenger lymphocytes. since the best result was 
obtained in the heart graft in this study. 
Development of GVHD in small howel plus bone mar-
row recipients suggests that the quality. as well as the 
quantity. of whole donor inoculum afiects the subsequent 
host-graft relationship. Further strategies tll improve graft 
survival may be necessary. 
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